Pipeline | Immune Design

G100

Potent Intratumoral TLR4 agonist

• Intratumoral immune activation of the tumor microenvironment
• Designed to leverage endogenous antigens and create a systemic immune response

ABOUT G100: G100 is Immune Design’s lead product candidate and is designed to leverage the range of endogenous antigens (including neoantigens) found in the tumor microenvironment to create a systemic anti-tumor immune response from local injection. At its core, G100 consists of Glucopyranosyl Lipid A (GLA), a potent small synthetic molecule that selectively binds to the Toll-like Receptor-4 (TLR4) receptor. We believe this causes dendritic cells to activate, capture endogenous tumor antigens and induce a broad, anti-tumor immune response specifically relevant to each patient’s tumor type. In addition, certain tumor types such as follicular lymphoma express TLR4, which may enable G100 to have a dual mechanism of anti-cancer activity.

STATUS: G100 has been studied in multiple clinical trials. Importantly, G100 has demonstrated both single agent activity and shown benefit in combination with local, low-dose radiation and the anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab). Patients whose tumors expressed TLR4 at baseline had a significantly improved overall response rate. G100 had been well tolerated and, importantly, tumor biopsies show increased inflammatory responses and T cell infiltrates in abscopal, non-treated tumors.  (See Presentations)

We have received Orphan Drug Designation in follicular lymphoma for G100 in the US and have had discussions with the U.S. Food and Drug Administration regarding an unmet need population for patients who have failed three or more lines of therapy. The company plans to pursue further development of G100, initially in this patient population, and intends to expand development into earlier lines of therapy within lymphoma, other B-cell malignancies as well as certain solid tumors.

Please check the clinical trials page for more information.